Reviewing Oncobiologics (NASDAQ:OTLK) and Equillium (NASDAQ:EQ)

Oncobiologics (NASDAQ:OTLK – Get Free Report) and Equillium (NASDAQ:EQ – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, risk and earnings.

Volatility and Risk

Oncobiologics has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500. Comparatively, Equillium has a beta of 2.08, meaning that its stock price is 108% more volatile than the S&P 500.

Profitability

This table compares Oncobiologics and Equillium’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Oncobiologics N/A N/A -254.82%
Equillium N/A -38.23% -35.85%

Analyst Recommendations

This is a summary of recent recommendations and price targets for Oncobiologics and Equillium, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oncobiologics 1 2 2 0 2.20
Equillium 1 1 8 2 2.92

Oncobiologics presently has a consensus price target of $5.20, indicating a potential upside of 1,213.13%. Equillium has a consensus price target of $7.12, indicating a potential upside of 519.57%. Given Oncobiologics’ higher probable upside, equities analysts plainly believe Oncobiologics is more favorable than Equillium.

Earnings and Valuation

This table compares Oncobiologics and Equillium”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Oncobiologics $1.35 million 71.41 -$62.42 million ($0.77) -0.51
Equillium $41.10 million 1.77 -$22.40 million ($0.18) -6.39

Equillium has higher revenue and earnings than Oncobiologics. Equillium is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

11.2% of Oncobiologics shares are owned by institutional investors. Comparatively, 27.1% of Equillium shares are owned by institutional investors. 1.8% of Oncobiologics shares are owned by insiders. Comparatively, 17.8% of Equillium shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Equillium beats Oncobiologics on 10 of the 13 factors compared between the two stocks.

About Oncobiologics

(Get Free Report)

Oncobiologics, Inc. changed its name to Outlook Therapeutics, Inc. in 2018 and trades under the symbol OTLK. The biotechnology company focuses on developing and commercializing treatments for eye diseases. Its lead product, Lytenava (bevacizumab gamma), is an ophthalmic formulation of bevacizumab developed to treat neovascular age-related macular degeneration, also known as wet AMD. The company has pursued regulatory approvals and commercialization of the treatment in the United States and Europe.

About Equillium

(Get Free Report)

Equillium is a biotechnology company focused on developing medicines that target immune pathways involved in autoimmune and inflammatory diseases. Its research has centered on treatments for conditions with significant unmet medical needs. The company’s leading program has been itolizumab, a monoclonal antibody that targets CD6, an immune-cell protein. Equillium obtained development and commercialization rights to itolizumab from India-based Biocon for several markets, including the United States, Canada, Australia and New Zealand.

Receive News & Ratings for Oncobiologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncobiologics and related companies with MarketBeat.com's FREE daily email newsletter.